Get the Stockscreener App
47.33
5.81%
2.60
After Hours:
47.84
0.51
+1.08%
Genedx Holdings Corp stock is traded at $47.33, with a volume of 2.28M.
It is up +5.81% in the last 24 hours and down -30.50% over the past month.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
See More
Previous Close:
$44.73
Open:
$44.96
24h Volume:
2.28M
Relative Volume:
2.00
Market Cap:
$1.41B
Revenue:
$442.68M
Net Income/Loss:
$-77.81M
P/E Ratio:
-17.74
EPS:
-2.6684
Net Cash Flow:
$-28.65M
1W Performance:
+21.83%
1M Performance:
-30.50%
6M Performance:
-67.70%
1Y Performance:
-30.17%
1-Day Range:
$43.91
$49.43
1-Week Range:
$37.64
$49.43
52-Week Range:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
888-729-1206
Address
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
47.33 | 1.33B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
449.37 | 167.89B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
173.33 | 121.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
553.07 | 43.67B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
340.99 | 33.51B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.79 | 32.15B | 7.07B | 1.29B | 993.00M | 4.5355 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-15-25 | Initiated | Guggenheim | Buy |
| May-09-25 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
View All
Genedx Holdings Corp Stock (WGS) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp.WGS - PR Newswire
WGS stock slumps after hours as firm predicts lower test volume for year - MSN
Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares? - The Motley Fool
Casdin Partners master fund buys $21.5 million in GeneDx stock By Investing.com - Investing.com South Africa
Casdin Partners master fund buys $21.5 million in GeneDx stock - Investing.com
Casdin-linked funds add 500K GeneDx (WGS) shares in open-market buys - Stock Titan
GeneDx Holdings (WGS) price target decreased by 32.59% to 98.94 - MSN
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud - marketscreener.com
GeneDx Holdings Corp. (WGS) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
GeneDx faces securities fraud probe after missing revenue targets and stock plunges 49%. - Pluang
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Law firm investigates GeneDx after shares plunge 50% on weak earnings and lowered guidance - Pluang
FinancialContentBragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. (NASDAQ:WGS) on Behalf of GeneDx Stockholders and Encourages Investors with Losses to Contact the Firm - FinancialContent
GeneDx Holdings Corp.Class A Common Stock (NQ: WGS - The Chronicle-Journal
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect? - MSN
GeneDx Holdings Insider Bought Shares Worth $13,765,345, According to a Recent SEC Filing - marketscreener.com
A Look At GeneDx Holdings (WGS) Valuation After Q1 2026 Reset And Securities Investigation - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdin - The National Law Review
(WGS) Risk Channels and Responsive Allocation - Stock Traders Daily
Comerica Bank Sells 29,753 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
GeneDx Fraud Probes And Guidance Cut Put Valuation Gap In Focus - simplywall.st
Number of shareholders of GeneDx Holdings Corp. – NASDAQ:WGS - TradingView
A Look At GeneDx Holdings (WGS) Valuation After Earnings Miss Guidance Cut And Securities Investigation - Yahoo Finance
GeneDx Holdings (WGS) upgraded to strong buy: Here's what you should know - MSN
UBS Group AG Decreases Stake in GeneDx Holdings Corp. $WGS - MarketBeat
Corvex management, director Keith Meister buy $13.7m GeneDx stock By Investing.com - Investing.com South Africa
Corvex management, director Keith Meister buy $13.7m GeneDx stock - Investing.com India
Corvex-linked funds boost GeneDx (WGS) stake with 351K-share open-market buy - Stock Titan
Casdin and Meister report 12% and 17.9% GeneDx (WGS) stakes - Stock Titan
GeneDx (NASDAQ:WGS) Shares Up 6.9%Still a Buy? - MarketBeat
GeneDx WGS Slides On Guidance Cut As Insiders Buy The Dip - StocksToTrade
GeneDx expects $475M-$490M 2026 revenue as it targets at least 30% exome/genome volume growth - MSN
GeneDx Q1 2026 misses targets; lower-margin genomic tests slow growth, but turnaround potential remains. - Pluang
GeneDx (WGS) Fell Despite Continued Execution Improvement - Insider Monkey
Levi & Korsinsky Announces Investigation of Securities Claims Against GeneDx Holdings Corp. (WGS) - GlobeNewswire
GeneDx: Disappointing Q1 Creates Another Turnaround Opportunity (NASDAQ:WGS) - Seeking Alpha
GeneDx Holdings, Duolingo, Kosmos Energy and other big stocks moving lower in Tuesday's pre-market session - MSN
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - ChartMill
WGS Investor Alert: Levi & Korsinsky Investigates GeneDx Holdings Corp. (WGS) for Potential Securities Fraud - Morningstar
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Just Slashed This Year's Revenue Estimates By 12% - simplywall.st
GeneDx: The 50% Crash Creates A Compelling Entry (NASDAQ:WGS) - Seeking Alpha
Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - FinancialContent
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect | NDAQ:WGS | Press Release - Stockhouse
Monday’s insider activity: GeneDx director buys $46.8M in stock By Investing.com - Investing.com Australia
Monday’s insider activity: GeneDx director buys $46.8M in stock - Investing.com UK
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Casdin Capital, LLC | Director |
May 18 '26 |
Buy |
42.55 |
175,000 |
7,446,547 |
3,182,164 |
| Casdin Capital, LLC | Director |
May 20 '26 |
Buy |
43.81 |
140,000 |
6,132,854 |
3,507,164 |
| Meister Keith A. | Director |
May 13 '26 |
Buy |
39.09 |
165,000 |
6,449,983 |
4,598,297 |
| Meister Keith A. | Director |
May 14 '26 |
Buy |
39.39 |
140,000 |
5,514,790 |
4,738,297 |
| Meister Keith A. | Director |
May 15 '26 |
Buy |
38.91 |
46,273 |
1,800,571 |
4,784,570 |
| Meister Keith A. | Director |
May 07 '26 |
Buy |
37.86 |
533,758 |
20,207,189 |
3,761,908 |
| Meister Keith A. | Director |
May 11 '26 |
Buy |
39.29 |
500,000 |
19,642,789 |
4,433,297 |
| Meister Keith A. | Director |
May 08 '26 |
Buy |
40.59 |
171,389 |
6,956,751 |
3,933,297 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Apr 29 '26 |
Option Exercise |
0.00 |
3,874 |
0 |
95,388 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Apr 29 '26 |
Sale |
65.19 |
2,172 |
141,595 |
93,216 |
0.04%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):